A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03498716
- Collaborators
- Breast International Group
- Alliance Foundation Trials (AFT)
- Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)
- Frontier Science & Technology Research Foundation, Inc.
- Investigators
- Study Director: Clinical Trials Hoffmann-La Roche
Get Well Soon